Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Thalidomide is increasingly being used due to its effectiveness in the treatment of a variety of dermatologic conditions refractory to other treatments. Although thalidomide's side effects have been well-documented in the literature since its entry in the 1950s, some of the risks associated with its use are still being discovered. Recently, increased incidence of venous thrombosis following thalidomide use has been reported in the treatment of diseases with disease-related thrombotic risks, such as malignancy and lupus with antiphospholipid antibody syndrome, as well as concomitant therapy with chemotherapy and/or systemic corticosteroids. We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature. Our findings substantiate an increase in risk for thrombosis following thalidomide use in the dermatology and non-cancer clinical setting.
Fabi
Sabrina Guillen
SG
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA. sguillen@uic.edu
Hill
Carlotta
C
Witherspoon
Joslyn N
JN
Boone
Susan L
SL
West
Dennis P
DP
D000328:Adult; D004359:Drug Therapy, Combination; D004893:Erythema Nodosum / Q000188:drug therapy; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015440:Leprosy, Lepromatous / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000139:chemically induced*; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000139:chemically induced*
D007917:Leprostatic Agents; D013792:Thalidomide; D011241:Prednisone